Search Results
Search for other papers by Merlin C Thomas in
Google Scholar
PubMed
Search for other papers by Brendon L Neuen in
Google Scholar
PubMed
Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
Search for other papers by Stephen M Twigg in
Google Scholar
PubMed
Search for other papers by Mark E Cooper in
Google Scholar
PubMed
Department of Renal Medicine, St George Hospital, Sydney, NSW, Australia
Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia
Search for other papers by Sunil V Badve in
Google Scholar
PubMed
-pressure-independent renoprotective actions appear modest and limited to the prevention of new-onset macroalbuminuria ( 23 ). The use of high-potency statins in patients with CKD is also standard of care ( 15 ) because the CV risk of most people with T2D and CKD usually exceeds 10
Search for other papers by Chaiho Jeong in
Google Scholar
PubMed
Search for other papers by Bongseong Kim in
Google Scholar
PubMed
Search for other papers by Jinyoung Kim in
Google Scholar
PubMed
Search for other papers by Hansang Baek in
Google Scholar
PubMed
Search for other papers by Mee Kyoung Kim in
Google Scholar
PubMed
Search for other papers by Tae-Seo Sohn in
Google Scholar
PubMed
Search for other papers by Ki-Hyun Baek in
Google Scholar
PubMed
Search for other papers by Ki-Ho Song in
Google Scholar
PubMed
Search for other papers by Hyun-Shik Son in
Google Scholar
PubMed
Search for other papers by Kyungdo Han in
Google Scholar
PubMed
Search for other papers by Hyuk-Sang Kwon in
Google Scholar
PubMed
dichotomized at the lowest 25%. We defined a statin user as a person who had a prescription of a statin within 1 year of health examination. Blood samples for measurements of serum glucose, creatinine, and lipid levels were drawn after an overnight fast. Blood
Search for other papers by Hui-qing Yuan in
Google Scholar
PubMed
Search for other papers by Jia-xi Miao in
Google Scholar
PubMed
Search for other papers by Jia-ping Xu in
Google Scholar
PubMed
Search for other papers by Su-xiang Zhu in
Google Scholar
PubMed
Search for other papers by Feng Xu in
Google Scholar
PubMed
Search for other papers by Xiao-hua Wang in
Google Scholar
PubMed
Search for other papers by Chun-hua Wang in
Google Scholar
PubMed
Search for other papers by Chao Yu in
Google Scholar
PubMed
Search for other papers by Xue-qin Wang in
Google Scholar
PubMed
Search for other papers by Jian-bin Su in
Google Scholar
PubMed
Search for other papers by Dong-mei Zhang in
Google Scholar
PubMed
as age, sex and blood pressure), medical history (such as diabetes duration, history of hypertension and smoking), prescription information (such as glucose-lowering therapies and statins treatments), and biochemical measurements. Glucose
Search for other papers by Wang-shu Liu in
Google Scholar
PubMed
Search for other papers by Ling-yan Hua in
Google Scholar
PubMed
Search for other papers by Su-xiang Zhu in
Google Scholar
PubMed
Search for other papers by Feng Xu in
Google Scholar
PubMed
Search for other papers by Xue-qin Wang in
Google Scholar
PubMed
Search for other papers by Chun-feng Lu in
Google Scholar
PubMed
Search for other papers by Jian-bin Su in
Google Scholar
PubMed
Search for other papers by Feng Qi in
Google Scholar
PubMed
statin medications, lipid profile or UA level ( P for trend >0.05). Table 1 Clinical characteristics of the study participants. Normally distributed values in the table are given as the mean ± s.d. , skewed distributed values are given as the
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Xiaohui Qi in
Google Scholar
PubMed
Search for other papers by Ping He in
Google Scholar
PubMed
Search for other papers by Huayan Yao in
Google Scholar
PubMed
Search for other papers by Huanhuan Sun in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Jiying Qi in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Min Cao in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Bin Cui in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Guang Ning in
Google Scholar
PubMed
biguanides, dipeptidyl peptidase 4 inhibitors, sulfonylureas, thiazolidinediones, calcium channel blockers, statin, and aspirin. Propensity score matched method In consideration that the baseline characteristics might be imbalanced between insulin
Search for other papers by Cheryl M Isherwood in
Google Scholar
PubMed
Search for other papers by M Denise Robertson in
Google Scholar
PubMed
Search for other papers by Debra J Skene in
Google Scholar
PubMed
Search for other papers by Jonathan D Johnston in
Google Scholar
PubMed
lean group was a smoker and was required to refrain from smoking for 1 week before the study. Two T2D participants were diet and exercise controlled (no medication) and five participants were treated with combinations of metformin, statins, ramipril and
Search for other papers by Clemens Kamrath in
Google Scholar
PubMed
Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
Search for other papers by Alexander Eckert in
Google Scholar
PubMed
Search for other papers by Birgit Rami-Merhar in
Google Scholar
PubMed
Search for other papers by Sebastian Kummer in
Google Scholar
PubMed
Search for other papers by Martin Wabitsch in
Google Scholar
PubMed
Search for other papers by Katharina Laubner in
Google Scholar
PubMed
Search for other papers by Florian Kopp in
Google Scholar
PubMed
Search for other papers by Silvia Müther in
Google Scholar
PubMed
Search for other papers by Steffen Mühldorfer in
Google Scholar
PubMed
Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
Search for other papers by Reinhard W Holl in
Google Scholar
PubMed
.0 4.0 4.8 ns ns 0.002 ns SGLT2 inhibitors 0.3 4.5 4.0 7.1 ns ns <0.001 ns Lipid-lowering drugs 6.9 28.3 28.0 19.1 0.001 ns ns ns Statins 6.4 26.4 8.0 16.7 ns ns ns ns
Centre for Biological Timing, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Search for other papers by Robert Maidstone in
Google Scholar
PubMed
Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester, UK
Search for other papers by Martin K Rutter in
Google Scholar
PubMed
Oxford Liver Unit, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, UK
Search for other papers by Thomas Marjot in
Google Scholar
PubMed
NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Search for other papers by David W Ray in
Google Scholar
PubMed
NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Search for other papers by Matthew Baxter in
Google Scholar
PubMed
fat metabolism is perturbed by shift work is an obvious and essential step. In addition, drugs targeting the liver may have differential effects depending on the time of day of administration. For example, statin drugs work best at night, and
Search for other papers by Qian Deng in
Google Scholar
PubMed
Search for other papers by Yue Zhu in
Google Scholar
PubMed
Search for other papers by Mengmeng Zhang in
Google Scholar
PubMed
Search for other papers by Aihua Fei in
Google Scholar
PubMed
Search for other papers by Jiaqi Liang in
Google Scholar
PubMed
Search for other papers by Jinjin Zheng in
Google Scholar
PubMed
Search for other papers by Qingping Zhang in
Google Scholar
PubMed
Search for other papers by Tong Cheng in
Google Scholar
PubMed
Search for other papers by Xia Ge in
Google Scholar
PubMed
statins and fibrates in the management of cardiovascular risk . Current Opinion in Lipidology 2009 20 505– 511 . ( https://doi.org/10.1097/MOL.0b013e328332e9ef ) 105 Xu N Wang Q Jiang S Wang Q Hu W Zhou S Zhao L Xie L Chen J Wellstein